Maintenance treatment for myasthenia gravis after efgartigimod
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of myasthenia gravis.
- You are already eligible to take efgartigimod, based on standard medical guidelines and a blood test.
- Your MG symptoms significantly affect daily life—either a score of 11 or more on the MG-ADL scale, or a score of 6 to 10 with most trouble coming from things other than eye symptoms.
- You have not had a previous B-cell depleting treatment (like rituximab) or certain other strong immune therapies.
- You do not have another active autoimmune disease (like lupus or rheumatoid arthritis) or an immune deficiency.
- You have not had a bad reaction to efgartigimod or similar drugs in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug called efgartigimod can help people with generalized myasthenia gravis who have recently had a severe flare-up. Participants will get the drug as maintenance therapy to prevent future crises.
This trial tests whether taking two drugs one after the other—efgartigimod followed by telitacicept—is safe and effective for people with generalized myasthenia gravis. It may offer a new treatment option if standard therapy isn't enough.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This study looks at how safe efgartigimod is for people with generalized myasthenia gravis (gMG), whether they are taking the drug now, will start it soon, or are not taking it at all.
This trial tests giving a medication called efgartigimod before and after surgery for people who have both thymoma (a thymus tumor) and myasthenia gravis. The goal is to see if it helps improve muscle strength and recovery after tumor removal.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.